Abstract:Abstract Conventional therapies target rapidly proliferating non-tumorigenic cells and spare the relatively quiescent cancer stem cells (CSCs) and the CSCs will remain viable after therapy and re-establish the tumor. Thus developing therapeutic strategies to target CSCs to prevent tumor recurrence will be vital for cancer therapy. To date, it has been shown that CSCs in hepatocellular carcinoma (HCC) can be identified by several cell surface antigens CD133, CD90, CD44, OV6 and the epithelial cell adhesion molecule (EpCAM). Here, we developed a novel strategy which targeted CSCs by anti-CD44 antibody mediated nanoparticles delivery system loaded with a triple fusion gene containing the suicide gene-herpes simplex virus truncated thymidine kinase (TTK), renilla luciferase (RL) and RFP (TF, RL-RFP-TTK). The in situ liver cancer model was established by injection of 1.0×105 HepG2 cells, which carry a reporter system encoding the genes of firefly luciferase (FL) and GFP into the liver of NOD/SCID mice. The mice were subsequently treated with ganciclovir (GCV). Then the growth status of tumor was monitored by the optical bioluminescence imaging of firefly luciferase(FL) and the specific targeting of the nanoparticles was tracked by imaging of renilla luciferase(RL). Our results demonstrated that the anti-CD44 antibody mediated nanoparticles loaded with TTK could specifically target the CSCs of HCC, and thereafter were endocytosed by the plasma membrane to transport the triple fusion (TF, RL-RFP-TTK) into the cells, resulted in the apoptosis of the targeted cells. Taken together, our study demonstrated a novel therapeutic strategy by targeted CSCs, we also developed a useful multimodality imaging techniques to monitor HepG2 cells’ fate in vivo and assessed the targeting efficacy of the nanoparticles. This may open a new application for the treatment of the HCC by targeting CSCs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2464. doi:10.1158/1538-7445.AM2011-2464

A Novel Antibody Targeting CD24 and Hepatocellular Carcinoma in Vivo by Near-Infrared Fluorescence Imaging

Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.

Integrin Α6 Targeted Near Infrared Fluorescent Imaging and Photoacoustic Imaging of Hepatocellular Carcinoma in Mice

CD44 Antibody-Targeted Liposomal Nanoparticles for Molecular Imaging and Therapy of Hepatocellular Carcinoma

A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma

Selective Targeted Delivery of Doxorubicin Via Conjugating to Anti-Cd24 Antibody Results in Enhanced Antitumor Potency for Hepatocellular Carcinoma Both in Vitro and in Vivo

CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy

In Vivo Fluorescence Imaging of Hepatocellular Carcinoma Using a Novel GPC3-specific Aptamer Probe

Multi-modal Imaging for Uptake of Peptide Ligand Specific for CD44 by Hepatocellular Carcinoma

NIR-II Imaging of Hepatocellular Carcinoma Based on a Humanized Anti-Gpc3 Antibody

Abstract 2464: Targeting Liver Cancer Stem Cells for Molecular Imaging and Therapeutic Application

A Novel Antibody-Drug Conjugate, HcHAb18-DM1, Has Potent Anti-Tumor Activity Against Human Non-Small Cell Lung Cancer

A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and αvβ3 for treating cancer and regulating the tumor microenvironment

Detection of Hepatocellular Carcinoma in an Orthotopic Patient-Derived Xenograft with an Epithelial Cell Adhesion Molecule-Specific Peptide

Development of a DNA Aptamer Against Multidrug-Resistant Hepatocellular Carcinoma for in Vivo Imaging.

Imaging of Hepatocellular Carcinoma Patient-Derived Xenografts Using 89Zr-Labeled Anti-Glypican-3 Monoclonal Antibody

Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes.

[In-Vivo Targeted Imaging of Hepatocellular Carcinoma in Nude Mice Using Quantum Dot Probes].

Targeting CD24 in Cancer Immunotherapy

Visualization of nonsmall-cell lung cancer by near-infrared fluorescence imaging with tumor-targeting peptide ABT-510